The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries

The potential for reducing the number of pneumococcal conjugate vaccine doses while sustaining herd immunity in high-income countries

Bibliographic Details
Main Authors:	Flasche, S, Van Hoek, AJ, Goldblatt, D, Edmunds, WJ, O’Brien, KL, Scott, JAG, Miller, E
Format:	Journal article
Language:	English
Published:	Public Library of Science 2015

Similar Items

The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries.
by: Stefan Flasche, et al.
Published: (2015-06-01)

Pneumococcal conjugate vaccine dose-ranging studies in humans: a systematic review
by: Lucinde, RK, et al.
Published: (2021)

The serotype distribution among healthy carriers before vaccination is essential for predicting the impact of pneumococcal conjugate vaccine on invasive disease.
by: Stefan Flasche, et al.
Published: (2015-04-01)

Herd protection induced by pneumococcal conjugate vaccine
by: Keith P Klugman
Published: (2014-07-01)

Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam
by: Olivier Le Polain De Waroux, et al.
Published: (2018-08-01)

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease
by: Edmunds W John, et al.
Published: (2010-04-01)

From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy
by: Nivaldo Linares-Pérez, et al.
Published: (2017-07-01)

Comparison of two schedules of two-dose priming with the ten-valent pneumococcal conjugate vaccine in Nepalese children: an open-label, randomised non-inferiority controlled trial
by: Kandasamy, R, et al.
Published: (2019)

Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
by: Flasche, S, et al.
Published: (2017)

Effect of pneumococcal conjugate vaccination on serotype-specific carriage and invasive disease in England: a cross-sectional study.
by: Stefan Flasche, et al.
Published: (2011-04-01)

Pneumococcal conjugate vaccine implementation in middle-income countries
by: Tricarico, Serena, et al.
Published: (2017)

The immunogenicity and impact on nasopharyngeal carriage of fewer doses of conjugate pneumococcal vaccine immunization schedule.
by: Ota, M, et al.
Published: (2011)

Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
by: Cornelis H. van Werkhoven
Published: (2017-05-01)

Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
by: Stefan Flasche, et al.
Published: (2017-06-01)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
by: Adamu, AL, et al.
Published: (2023)

Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.
by: Lindsay R Grant, et al.
Published: (2013-01-01)

Pneumococcal Infection among Children before Introduction of 13-Valent Pneumococcal Conjugate Vaccine, Cambodia
by: Paul Turner, et al.
Published: (2015-11-01)

Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England.
by: Albert Jan van Hoek, et al.
Published: (2016-01-01)

A cost-effectiveness analysis of pneumococcal conjugate vaccines in infants and herd protection in older adults in Colombia
by: Jaime E. Ordóñez, et al.
Published: (2023-12-01)

Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.
by: Gabriela García Gabarrot, et al.
Published: (2014-01-01)

Persistence of immunity following 2-dose priming with a 10-valent pneumococcal conjugate vaccine at 6 and 10 weeks or 6 and 14 weeks of age in Nepalese toddlers
by: Gurung, M, et al.
Published: (2021)

Detection of pneumococcal DNA in blood by polymerase chain reaction for diagnosing pneumococcal pneumonia in young children From low- and middle-income countries
by: Morpeth, SC, et al.
Published: (2017)

Impact of pneumococcal conjugate vaccines for children in high- and non–high-income countries
by: Robert Cohen, et al.
Published: (2017-06-01)

The antibody response following a booster with either a 10- or 13-valent pneumococcal conjugate vaccine in toddlers primed with a 13-valent pneumococcal conjugate vaccine in early infancy.
by: Trück, J, et al.
Published: (2016)

Herd immunity alters the conditions for performing dose schedule comparisons: an individual-based model of pneumococcal carriage
by: Alan Yang, et al.
Published: (2019-03-01)

Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis
by: Cynthia Chen, PhD, et al.
Published: (2019-01-01)

Invasive Pneumococcal Disease after Routine Pneumococcal Conjugate Vaccination in Children, England and Wales
by: Shamez N. Ladhani, et al.
Published: (2013-01-01)

Pneumococcal vaccine schedules (PVS) study: a cluster-randomised, non-inferiority trial of an alternative versus standard schedule for pneumococcal conjugate vaccination—statistical analysis plan
by: Grant A. Mackenzie, et al.
Published: (2022-12-01)

Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
by: Rodgers, G, et al.
Published: (2013)

Pneumococcal conjugate vaccine induced IgG and nasopharyngeal carriage of pneumococci: Hyporesponsiveness and immune correlates of protection for carriage
by: Ojal, J, et al.
Published: (2017)

Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands
by: Anna M.M. van Deursen, et al.
Published: (2012-11-01)

Pneumococcal vaccination in persons living with HIV: Pneumococcal conjugate, polysaccharide or both?
by: Bhavna Dhingra, et al.
Published: (2020-12-01)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012-03-01)

Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study
by: Shrestha, S, et al.
Published: (2022)

How Many is Enough? Will Conjugated Pneumococcal Vaccines With More Serotypes and Fewer Doses Work Better?
by: Chun-Yi Lu, et al.
Published: (2011-02-01)

Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites.
by: Daniel R Feikin, et al.
Published: (2013-01-01)

Elucidating the impact of the pneumococcal conjugate vaccine programme on pneumonia, sepsis and otitis media hospital admissions in England using a composite control
by: Dominic Thorrington, et al.
Published: (2018-02-01)

Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Greenland
by: Kristiana Alexandrova Nikolova, et al.
Published: (2021-10-01)

The impact of introduction of the 10-valent pneumococcal conjugate vaccine on pneumococcal carriage in Nigeria
by: Aishatu L. Adamu, et al.
Published: (2023-05-01)

Nasopharyngeal Pneumococcal Colonization among Children after Pneumococcal Conjugate Vaccine Introduction
by: Manoochehr Karami, et al.
Published: (2017-08-01)